Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

References

• NICE appraisal no. 53. [http://www.nice.org.uk/page.aspx?o=TA053] (accessed 28th April 2006)
   Google Scholar
• Prescription cost analysis for England. (accessed 28th April 2006) [http://www.ic.nhs.uk/pubs/prescostanalysis2005]
   Google Scholar
• Bagust A, Evans M, Beale et al. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. Pharmacoeconomics 2006;24(Suppl 1):5–19
   PubMedGoogle Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
   Google Scholar
• Turner RC, Milns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823–8
   PubMed Web of Science ®Google Scholar
• Davis EA, Keating B, Byrne GC, et al. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child 1998;78:111–15
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CLl, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34
   PubMed Web of Science ®Google Scholar
• Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577–80
   PubMed Web of Science ®Google Scholar
• Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE901 versus NPH insulin patients with type 1 diabetes. Diabetes Care 2000;23:157–62
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog Lantus (HOE901) and NPH human insulin with insulin lispro inpatients with type 1 diabetes. Diabetes Care 2000;23:1666–71
   PubMed Web of Science ®Google Scholar
• Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005;21: 545–53
   Google Scholar
• Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:369–76
   Google Scholar
• Ratner R, Hirsch IB, Niefing JL, et al. Less hypoglycaemia with Lantus in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639–43
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Park G, Zimmerman J. Basal Lantus (HOE901) versus NPH insulin in patients with type 1 diabetes or multiple daily insulin regimens. Diabetes Care 2000;23: 1137–42
   Google Scholar
• Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in Type 2 diabetes 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631–6
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine (HOE 901) versus NPH insulin during combination therapy in type 2 diabetes. Diabetes Care 2000;23: 1130–6
   Google Scholar
• Riddle MR, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 patients. Diabetes Care 2003;26: 3080–6
   Google Scholar
• Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005;35:536–42
   Google Scholar
• Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 2003;26:1490–6
   PubMed Web of Science ®Google Scholar
• Porcellatti F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given mealtime lispro insulin. Diabet Med 2004;21:1213–20
   PubMed Web of Science ®Google Scholar
• Murphy N, Keane S, Ong K, et al. A randomized crossover trial comparing insulin glargine plus insulin lispro with NPH insulin plus soluble insulin in adolescents with type 1 diabetes. Diabetologia 2002;45(Suppl 2):871
   Google Scholar
• Fritsche A, Schweitzer MA, Häring H. Improved glycaemic control and reduced nocturnal hypoglycaemia in patients with type 2 diabetes with morning administration of insulin glargine compared with NPH insulin. Diabetes Care 2002;51 (Suppl 2):149
   Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004;13:437–52
   PubMed Web of Science ®Google Scholar
• Poole CD, Tetlow T, McEwan P, et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S41–48
   Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the UK Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47: 1747–59
   Google Scholar
• Rosenstock J, Park G, Zimmerman J. Basal Lantus (HOE901) versus NPH insulin in patients with type 1 diabetes or multiple daily insulin regimens. Diabetes Care 2000;23: 1137–42
   Google Scholar
• Medical Research Matters Limited. Insulin glargine and insulin detemir for type 1 and type 2 diabetes: systematic review of randomised controlled trials. Report for sanofi-aventis, January 2006 (data on file sanofi-aventis, Guildford).
   Google Scholar
• Pampanelli S, Fanelli C, Lalli C, et al. Long-term intensive therapy in IDDM: effects on HbA1c, risk of severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia 1996;39:677–86
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176–80
   PubMed Web of Science ®Google Scholar
• HOE-901/4002. Target glycaemic control and the incidence of symptomatic nocturnal hypoglycaemia in insulin naïve subjects with Type 2 diabetes on oral hypoglycaemic agent(s) and treated with insulin glargine or NPH human insulin. Data on file, sanofi-aventis, Guildford, Surrey, UK: 2002
   Google Scholar
• UK Treasury discount rates [http://www.hm-treasury.gov.uk/economic_data_and_tools/gdp_deflators/data_gdp_index.cfm] (accessed 28th April 2006)
   Google Scholar
• Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Med 2003;20:442–50
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type 1 diabetes: a Swiss perspective. Diabetologia 2000;43:13–26
   PubMed Web of Science ®Google Scholar
• UK Drug tariff, December 2005 <http://www.ppa.nhs.uk/edt/ december_2005/mindex.htm> (accessed 2nd May, 2006)
   Google Scholar
• McEwan P, Dixon S, Baboolal K, et al. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immuno-suppression following renal transplantation in the UK. Pharmacoeconomics 2006;24:67–79
   PubMed Web of Science ®Google Scholar
• NHS Reference costs [http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/NHSReferenceCosts/fs/en] (accessed 2nd May, 2006)
   Google Scholar
• Costs of glargine from the BNF [http://www.bnf.org/bnf/] (accessed 2nd May, 2006)
   Google Scholar
• O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3: 7
   Google Scholar
• Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581–90
   PubMed Web of Science ®Google Scholar
• Morgan CLl, McEwan P, Morrissey M, et al. Characterisation and comparison of health-related utility in people with diabetes in various states of single and multiple vascular complications. Diabetic Med 2007 (in press)
   Google Scholar
• Currie CJ, Poole CD, Tetlow T, et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S33–39
   Google Scholar
• McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S7–19
   PubMedGoogle Scholar
• Lee AJ, Morgan CLl, Conway P and Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin 2005;21:1777–83
   Google Scholar